Evidence map›Paper›PMID 42444815›Full record

ArticleFrontiers in oncology2026

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

Cainan Yu, Minghua Zhang, Jie Hui, Mengqing Zhu, Zengtian Sun, Yueyue Sun, Qian Sun, Zhiling Yan, Feng Zhu, Mingshan Niu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cainan YuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Minghua ZhangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jie HuiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Mengqing ZhuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zengtian SunDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yueyue SunDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qian SunDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhiling YanDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Feng ZhuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Mingshan NiuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Depeng LiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Kunming QiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Limited research is currently available regarding the prognostic value of Fc receptor-like 5 (FCRL5) in newly diagnosed multiple myeloma (NDMM). This study aimed to investigate the association of FCRL5 expression with treatment response and survival outcomes in NDMM patients, with a goal of providing insights for early risk stratification. Methods: We retrospectively analyzed a cohort comprising 54 NDMM patients treated between January 2024 and January 2025 at a single center. Pretreatment FCRL5 expression was quantified by flow cytometry, and the median value (75.15%) was utilized to stratify patients into two groups: high expression group and low expression group for comparison of baseline characteristics, treatment response, and survival outcomes. Results: Baseline characteristics, including age and disease stage, were balanced between the two FCRL5 expression groups, with all Conclusion: High FCRL5 expression was significantly associated with inferior response depth and survival in NDMM. Our findings suggested that FCRL5 may serve as a valuable biomarker for risk stratification, though further prospective validation is required.

Indexed as

Fc receptor-like 5 (Fcrl5)multiple myelomaprognosissurvival analysistreatment outcome

Identifiers

PMID42444815
PMCPMC13357220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.